• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Philip Morris International Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    10/29/25 4:05:56 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    false 0001413329 0001413329 2025-10-27 2025-10-27 0001413329 us-gaap:CommonStockMember 2025-10-27 2025-10-27 0001413329 pm:Notes2.750PercentDue2026Member 2025-10-27 2025-10-27 0001413329 pm:NotesDue2.875Percent2026Member 2025-10-27 2025-10-27 0001413329 pm:Notes0.125PercentDue2026Member 2025-10-27 2025-10-27 0001413329 pm:Notes3.125PercentDue2027Member 2025-10-27 2025-10-27 0001413329 pm:Notes3.125PercentDue2028Member 2025-10-27 2025-10-27 0001413329 pm:Notes2.875PercentDue2029Member 2025-10-27 2025-10-27 0001413329 pm:Notes3.375PercentDue2029Member 2025-10-27 2025-10-27 0001413329 pm:Notes2.750PercentDue2029Member 2025-10-27 2025-10-27 0001413329 pm:Notes3.750PercentDue2031Member 2025-10-27 2025-10-27 0001413329 pm:Notes0.800PercentDue2031Member 2025-10-27 2025-10-27 0001413329 pm:Notes3.250PercentDue2032Member 2025-10-27 2025-10-27 0001413329 pm:Notes3.125PercentDue2033Member 2025-10-27 2025-10-27 0001413329 pm:Notes2.000PercentDue2036Member 2025-10-27 2025-10-27 0001413329 pm:Notes1.875PercentDue2037Member 2025-10-27 2025-10-27 0001413329 pm:Notes6.375PercentDue2038Member 2025-10-27 2025-10-27 0001413329 pm:Notes1.450PercentDue2039Member 2025-10-27 2025-10-27 0001413329 pm:Notes4.375PercentDue2041Member 2025-10-27 2025-10-27 0001413329 pm:Notes4.500PercentDue2042Member 2025-10-27 2025-10-27 0001413329 pm:Notes3.875PercentDue2042Member 2025-10-27 2025-10-27 0001413329 pm:Notes4.125PercentDue2043Member 2025-10-27 2025-10-27 0001413329 pm:Notes4.875PercentDue2043Member 2025-10-27 2025-10-27 0001413329 pm:Notes4.250PercentDue2044Member 2025-10-27 2025-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 27, 2025

     

     

    Philip Morris International Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Virginia 1-33708 13-3435103

    (State or other jurisdiction

    of incorporation)

    (Commission File Number)

    (I.R.S. Employer

    Identification No.)

     

    677 Washington Blvd, Suite 1100

    Stamford, Connecticut

    06901
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (203) 905-2410

     

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, no par value   PM   New York Stock Exchange
    2.750% Notes due 2026   PM26A   New York Stock Exchange
    2.875% Notes due 2026   PM26   New York Stock Exchange
    0.125% Notes due 2026   PM26B   New York Stock Exchange
    3.125% Notes due 2027   PM27   New York Stock Exchange
    3.125% Notes due 2028   PM28   New York Stock Exchange
    2.875% Notes due 2029   PM29   New York Stock Exchange
    3.375% Notes due 2029   PM29A   New York Stock Exchange
    2.750% Notes due 2029   PM29D   New York Stock Exchange
    3.750% Notes due 2031   PM31B   New York Stock Exchange
    0.800% Notes due 2031   PM31   New York Stock Exchange
    3.250% Notes due 2032   PM32   New York Stock Exchange
    3.125% Notes due 2033   PM33   New York Stock Exchange
    2.000% Notes due 2036   PM36   New York Stock Exchange
    1.875% Notes due 2037   PM37A   New York Stock Exchange
    6.375% Notes due 2038   PM38   New York Stock Exchange
    1.450% Notes due 2039   PM39   New York Stock Exchange
    4.375% Notes due 2041   PM41   New York Stock Exchange
    4.500% Notes due 2042   PM42   New York Stock Exchange
    3.875% Notes due 2042   PM42A   New York Stock Exchange
    4.125% Notes due 2043   PM43   New York Stock Exchange
    4.875% Notes due 2043   PM43A   New York Stock Exchange
    4.250% Notes due 2044   PM44   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 8.01. Other Events.

     

    On October 29, 2025, Philip Morris International Inc. (“PMI”) issued $300,000,000 aggregate principal amount of its Floating Rate Notes due 2028 (the “Floating Rate Notes”), $750,000,000 aggregate principal amount of its 3.875% Notes due 2028 (the “2028 Notes”), $750,000,000 aggregate principal amount of its 4.000% Notes due 2030 (the “2030 Notes”), $850,000,000 aggregate principal amount of its 4.250% Notes due 2032 (the “2032 Notes”) and $850,000,000 aggregate principal amount of its 4.625% Notes due 2035 (the “2035 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2030 Notes and the 2032 Notes, the “Notes”). The Notes were issued pursuant to an Indenture dated April 25, 2008, by and between PMI and HSBC Bank USA, National Association, as trustee.

     

    In connection with the issuance of the Notes, on October 27, 2025, PMI entered into a Terms Agreement (the “Terms Agreement”) with BBVA Securities Inc., BofA Securities, Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Wells Fargo Securities, LLC, Goldman Sachs & Co. LLC, HSBC Securities (USA) Inc. and UBS Securities LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which PMI agreed to issue and sell the Notes to the Underwriters. The provisions of an Underwriting Agreement, dated April 25, 2008 (the “Underwriting Agreement”), are incorporated by reference in the Terms Agreement.

     

    PMI has filed with the Securities and Exchange Commission a Prospectus dated February 10, 2023 and a Prospectus Supplement (the “Prospectus Supplement”) dated October 27, 2025 (Registration No. 333-269690) in connection with the public offering of the Notes.

     

    PMI intends to add the net proceeds of the offering to its general funds, which may be used for general corporate purposes, to repay all or a portion of outstanding commercial paper, refinance its outstanding U.S. dollar denominated 4.875% Notes due 2026, U.S. dollar denominated 2.750% Notes due 2026 or euro denominated 2.875% Notes due 2026 or to meet its working capital requirements. Nothing contained in this Current Report on Form 8-K constitutes a notice of redemption of the U.S. dollar denominated 4.875% Notes due 2026, the U.S. dollar denominated 2.750% Notes due 2026 or the euro denominated 2.875% Notes due 2026.

     

    The Notes are subject to certain customary covenants, including limitations on PMI’s ability, with significant exceptions, to incur debt secured by liens and engage in sale/leaseback transactions. PMI may redeem the 2028 Notes, the 2030 Notes, the 2032 Notes and the 2035 Notes, in whole or in part, at the applicable redemption prices described in the Prospectus Supplement, plus accrued and unpaid interest thereon to, but excluding, the applicable redemption date. PMI may also redeem all, but not part, of the Notes of each series upon the occurrence of specified tax events as described in the Prospectus Supplement.

     

    Interest on the Floating Rate Notes is payable from October 29, 2025 quarterly in arrears on January 27, April 27, July 27 and October 27 of each year, commencing January 27, 2026, to holders of record on the preceding January 12, April 12, July 12 or October 12, as the case may be. Interest on the 2028 Notes is payable from October 29, 2025 semiannually in arrears on April 27 and October 27 of each year, commencing April 27, 2026, to holders of record on the preceding April 12 or October 12, as the case may be. Interest on the 2030 Notes is payable from October 29, 2025 semiannually in arrears on April 29 and October 29 of each year, commencing April 29, 2026, to holders of record on the preceding April 14 or October 14, as the case may be. Interest on the 2032 Notes is payable from October 29, 2025 semiannually in arrears on April 29 and October 29 of each year, commencing April 29, 2026, to holders of record on the preceding April 14 or October 14, as the case may be. Interest on the 2035 Notes is payable from October 29, 2025 semiannually in arrears on April 29 and October 29 of each year, commencing April 29, 2026, to holders of record on the preceding April 14 or October 14, as the case may be.

     

    The Floating Rate Notes will mature on October 27, 2028, the 2028 Notes will mature on October 27, 2028, the 2030 Notes will mature on October 29, 2030, the 2032 Notes will mature on October 29, 2032 and the 2035 Notes will mature on October 29, 2035.

     

    The Notes will be PMI’s senior unsecured obligations and will rank equally in right of payment with all of its existing and future senior unsecured indebtedness.

     

    For a complete description of the terms and conditions of the Underwriting Agreement, the Terms Agreement and the Notes, please refer to such agreements and the form of Notes, each of which is incorporated herein by reference and is an exhibit to this Current Report on Form 8-K as Exhibits 1.1, 1.2, 4.1, 4.2, 4.3, 4.4 and 4.5, respectively.

     

    Certain of the Underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory, commercial and investment banking services for PMI, for which they received or will receive customary fees and expenses. Certain of the Underwriters and their respective affiliates are lenders under PMI’s credit facilities. PMI and some of its subsidiaries may enter into foreign exchange and other derivative arrangements with certain of the Underwriters or their respective affiliates. In addition, certain of the Underwriters or their respective affiliates act as dealers in connection with PMI’s commercial paper programs.

     

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit 
    Number
    Description
       
    1.1 Underwriting Agreement, dated as of April 25, 2008 (incorporated by reference to Exhibit 1.1 of PMI’s Registration Statement on Form S-3 (No. 333-150449))
       
    1.2 Terms Agreement, dated October 27, 2025, among PMI and BBVA Securities Inc., BofA Securities, Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Wells Fargo Securities, LLC, Goldman Sachs & Co. LLC, HSBC Securities (USA) Inc. and UBS Securities LLC, as representatives of the several underwriters named therein
       
    4.1 Form of Floating Rate Notes due 2028
       
    4.2 Form of 3.875% Notes due 2028
       
    4.3 Form of 4.000% Notes due 2030
       
    4.4 Form of 4.250% Notes due 2032
       
    4.5 Form of 4.625% Notes due 2035
       
    5.1 Opinion of Hunton Andrews Kurth LLP
       
    104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101)

     

     

     

    SIGNATUREs

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PHILIP MORRIS INTERNATIONAL INC.
       
      By: /s/ DARLENE QUASHIE HENRY
      Name: Darlene Quashie Henry
      Title: Vice President, Associate General Counsel and Corporate Secretary

     

    DATE: October 29, 2025

     

     

    Get the next $PM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    More analyst ratings

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Evolves Organizational Model to Advance Smoke-Free Future

    Effective January 1, 2026, Philip Morris International will introduce new U.S. and International Business Units to enable continued industry-leading smoke-free progress Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) is today further detailing a new corporate organizational model announced in conjunction with the company's 2025 third quarter results. The updated organizational structure, effective January 1, 2026, is designed to enhance PMI's agility and support its journey to becoming a smoke-free company under the leadership of Group CEO PMI Jacek Olczak. PMI's smoke-free business is currently operating at scale across its regions, including substantial growth from th

    11/4/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Publishes Updated Climate Transition Plan to Achieve Net Zero by 2040

    The plan details actions, timelines, and targets for climate change mitigation and adaptation in the company's direct operations and the most vulnerable areas of its supply chain Philip Morris International Inc. (PMI) (NYSE:PM) today announced the release of its second Climate Transition Plan (CTP 2025), presenting an updated and integrated strategy to achieve net-zero greenhouse gas (GHG) emissions across its value chain by 2040. The new plan reflects PMI's continued commitment to a low-carbon future while aligning with science, regulatory frameworks, and stakeholder expectations, and builds on its 2021 Low-Carbon Transition Plan. Further, building on its 2022 Task Force on Climate-rel

    11/3/25 5:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    PMI U.S. Recognized for Workplace Excellence

    U.S. Businesses Honored as a Great Place to Work® and USA TODAY Top Workplace STAMFORD, Conn., Oct. 28, 2025 /PRNewswire/ -- Philip Morris International's U.S. businesses (PMI U.S.) is proud to announce its recent certification as a Great Place to Work® and recognition as a USA TODAY Top Workplace, including honors as a Top Woman-Led Company and for excellence in professional development, employee appreciation, and well-being. "Being nationally recognized for our culture and people-first approach is a testament to the incredible teams at PMI U.S.," said Stacey Kennedy, PMI U.S

    10/28/25 1:06:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Trumpaitis Mindaugas claimed ownership of 73,002 shares (SEC Form 3)

    3 - Philip Morris International Inc. (0001413329) (Issuer)

    6/9/25 3:34:30 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:43 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/9/25 4:54:34 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    11/4/25 7:06:32 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    10/29/25 4:05:56 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form FWP filed by Philip Morris International Inc

    FWP - Philip Morris International Inc. (0001413329) (Subject)

    10/27/25 6:57:10 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International upgraded by UBS with a new price target

    UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

    4/25/25 8:25:28 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

    In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

    3/4/24 6:48:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Reports 2025 Third-Quarter & First Nine-Months Results

    Raises Full-Year Adjusted Diluted EPS Guidance and Revises Assumptions; Third-Quarter Reported Diluted EPS Grew 13.2% to $2.23, Adjusted Diluted EPS Grew 17.3% to $2.24, and by 13.1% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 third quarter results.1 "In the third quarter, we continued to invest in the growth of our increasingly profitable smoke-free business, while achieving record quarterly smoke-free gross profit and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "Our global smoke-free portfolio is outgrowing the industry by a clear margin, driving positive total volumes, strong top-line growth an

    10/21/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Increases Dividend by 8.9% to Annualized Rate of $5.88 per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) has increased the company's regular quarterly dividend by 8.9% to an annualized rate of $5.88 per share. The new quarterly dividend of $1.47 per share, up from $1.35 per share, is payable on October 20, 2025, to shareholders of record as of October 3, 2025. The ex-dividend date is October 3, 2025. PMI has increased its annual dividend every year since becoming a public company in 2008, representing a total increase of 219.6%, or a compound annual growth rate of 7.1%. For additional dividend information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Ph

    9/19/25 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Second Quarter & First Six-Months Results and Raises Full-Year Guidance; Second Quarter Reported Diluted EPS Grew 26.6% to $1.95, Adjusted Diluted EPS Grew 20.1% to $1.91, and by 18.9% excluding currency

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 second quarter results.1 "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience. Given our strong year-to-date performance, we are raising our full-year guidance." _____________________________ 1 Explanation of PMI's use of non-GAAP me

    7/22/25 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care